12th International Society for Study of Xenobiotics (ISSX 2019)

Event Date: July 28 - August 1, 2019

Event Location: Oregon Convention Center, 777 NE Martin Luther King, Jr. Blvd, Portland, OR 97232

Diapharma is planning to attend the 12th International Society for Study of Xenobiotics (ISSX 2019) Meeting this year. Please click here to schedule a meeting with us or email us directly.

About ISSX 2019

ISSX 2019 is a meeting for the entire society that offers a broad ranging program to serve the interests of all its scientific and geographical constituencies.

ISSX 2019 Topics Include

Advances in the Role of Transporters in Drug Development
Predicting and Verifying Tissue Drug Concentrations Using a Proteomics and PET Imaging Approach
Advancing Predictions of Tissue and Intracellular Drug Concentrations Using in vitro and PBPK Modeling Approac hes
Influence of Transporter Polymorphisms on Drug Disposition and Response
Can BSEP Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk?
Transporter DDIs
Non-P450 Enzymes in ADMET for Drug Discovery and Development
Overview of Non-P450-mediated Metabolism in Drug Development
Role of Glucuronidation in Drug Metabolism and Toxicity
Enzymology and Clinical Importance of Reductases and Hydrolases
Significance of Hydrolases and Aldehyde Oxidase in Drug Toxicity
State of the Art PKPD and QSP Modeling
Introduction to QSP
How to Build a QSP Model in Less than One Hour
Application of QSP in Drug Discovery
Therapeutic Area Case Study: QSP in Immuno-oncology
Therapeutic Area Case Study: QSP in Inflammatory Disease
Idiosyncratic Drug-induced Liver Injury
The Role of Inflammatory Mediators in Idiosyncratic Drug-induced Liver Injury
Clinical Aspects of Hepatocellular and Cholestatic Drug-induced Liver Injury
Understanding Genetically-inherited Susceptibility Factors, Including HLA Genotype
Use of Pharmacogenomics and Other Patient-specific Factors to Individualize Drug Dosing and Treatment
Warfarin: A Paradigm for Individualized Dosing
Relevance of Transporter and Metabolic SNPs to Pediatric Treatment
CPIC Guidelines and Implementation to Date
Personalised Treatment of Cancer
State of the Art for Organs on Chips
Kidney Organoids for Disease Modeling and High Throughput Screening
Real-time Toxicity Assessment on Perfused 3D Epithelial Tubes
Tissues on Chips- A Novel Tool for Toxicity and Efficacy Testing on Human Tissue
Biofabrication of Liver Constructs for Drug Toxicity Studies
Quantitative Pharmacokinetic and Pharmacology Methods and Strategies in the Discovery and Development of Biotherapeutics
Development and Application of a PBPK Model for Large Molecules
PBPK and PKPD Modeling to Investigate Engineered Antibodies
PBPK Models for Predicting Human PK for Monoclonal Antibodies and Other Large Molecule Modalities
Systems PK/PD Model Informed Discovery and Development of Cancer Immunotherapy
Microbiome-Environment-Drug Interactions: Emerging Tools and Applications
Impact of Intestinal Flora on Host Metabolism of Drug, Sugar and Lipid
Activity-based Profiling of the Microbiome Response to Chemical Exposures
Impact of the Human Gut Microbiome on Drug Disposition
Developmental Reprogramming of the Gut Microbiota by Environmental Toxicants
Disease Effect on Transporter Regulation and Function
Proteomics Based Studies of Disease Effects on the Brain Barrier Transporters
Transporters in Polycystic Kidney Disease
Liver Transporter Activity in Patients with Renal Disease
Advances in the Study of Drug Metabolism
Predicting Routes, Sites, and Products of Metabolism
Substrate Recognition by Cytochrome P450s
Application of in silico DMPK in Drug Discovery and Development
Biosynthesis of Drug Candidates and Metabolites
Transporter Polymorphisms Drive Inter-ethnic Differences in Drug Response
Impact of Racial/Ethnic Differences in Drug Response: Regulatory Perspectives
State-of-the-Art Approaches in Drug Metabolizing Enzymes and Transporters (DMET) Biomarker Research: Path from Discovery to Validation
Biomarkers for in vivo Assessment of Transporter Function
Mechanistic Models for Coproporphyrin I and Creatinine as Endogenous Biomarkers for Transporter Drug-Drug Interactions
Knockout Mice, Transcriptomics and Metabolomics Approach for Discovery of Endogenous Biomarkers for Renal Drug Transporters
Integrated Quantitative Proteomics and Metabolomics Approach for Discovery and Validation of UGT2B17 Biomarker to Predict Drug Metabolism
Biotransformation Mechanisms and Pathways
Role of Albumin in Drug Disposition Revisited
Albumin-mediated Hepatic Uptake of Organic Anion Transport Polypeptide Substrates
Effects of Albumin on Prediction of Liver Kpuu and Human Hepatic Clearance for Enzyme- and Transporter-Mediated Mechanisms
Impact of Albumin and Plasma on the Renal Uptake of OAT1 Substrates
Ontogeny of Enzymes and Transporters and their Implications in Pediatric PBPK Modeling to Inform Pediatric Dosing
Ontogeny of Human Membrane Transporters: from Data to Application
Pediatric PBPK: Dealing with Uncertain Parameters and Deciding on Success Criteria for Predictability
‘Virtual Children’ to Inform Exposure-Controlled Dosing of Drugs in Children
Building, Verifying and Validating Pediatric PBPK Models: Vulnerabilities and Knowledge Deficits
ADME Issues Encountered and Addressed in Drug Discovery and Development
Management of MIST in a Case of Multiple Metabolic Species Differences

About ISSX

As the foremost organization representing the interests of researchers and educators in the field, the Society is engaged in multiple activities to support, promote, and advance the profession on a global scale.

ISSX Mission

ISSX advances research and education on the interplay of living systems with medicines and chemicals for the benefit of society worldwide.

ISSX Meetings

ISSX meetings bring together a network of academic and industry research scientists and future scientists in toxicology, pharmacology, molecular biology, and other disciplines related to the study of xenobiotics.

ISSX | Twitter | Facebook | LinkedIn | Oregon Convention Center